Company: BIAF
Filing Date: 2025-08-22
Form Type: DRS
Source: 0001641172-25-025247
Chunk: 5

Company: bioAffinity Technologies, Inc.
Filing Date: 2025-08-22
Form: DRS
Chunk 5
---
 The actual public offering price may be based upon a number of factors, including our history and our prospects, the industry in which we operate, our past and present operating results, the previous experience of our executive officers, and the general condition of the securities markets at the time of this offering.

Investing in our securities involves a high degree of risk. See “Risk Factors” beginning on page9 of this prospectus for a discussion of information that should be considered in connection with an investment in our securities. Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense.

|                                    |     | Per Share and    
 Common Stock     
 Purchase Warrant |     | Per Pre-Funded   
 Warrant and      
 Common Stock     
 Purchase Warrant |     | Total |
|:-----------------------------------|:----|:-----------------|:----|:-----------------|:----|:------|
| Public offering price              |     | $                |     | $                |     | $     |
| Placement Agent fees(1)            |     | $                |     | $                |     | $     |
| Proceeds to us, before expenses(2) |     | $                |     | $                |     | $     |

| (1) | We                                                                                                                                 
 have agreed to pay the Placement Agent a cash fee equal to [●]% of the aggregate gross proceeds raised in this offering. We        
 have also agreed to pay the Placement Agent a management fee equal to [●]% of the gross proceeds raised in this offering and       
 to reimburse the Placement Agent for certain of its offering related expenses, including reimbursement for legal fees and expenses 
 in the amount of up to $[●], non-accountable expenses of $[●] and for its clearing expenses in the amount of $[●].                 
 In addition, we have agreed to issue the Placement Agent or its designees warrants to purchase a number of shares of Common Stock  
 equal to [●]% of the shares of Common Stock sold in this offering (including the shares of Common Stock issuable upon the exercise 
 of the Pre-Funded Warrants), at an exercise price of $[●] per share, which represents [●]% of the public offering price            
 per share and accompanying August 2025 Warrants (“Placement Agent Warrants”). For a description of the compensation to             
 be received by the placement agent, see “Plan of Distribution